دورية أكاديمية
Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis
| العنوان: | Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis |
|---|---|
| المؤلفون: | Baccelli, Francesco, Gottardi, Francesca, Muratore, Edoardo, Leardini, Davide, Grasso, Antonio Giacomo, Gori, Davide, Belotti, Tamara, Prete, Arcangelo, Masetti, Riccardo |
| المساهمون: | Baccelli, Francesco, Gottardi, Francesca, Muratore, Edoardo, Leardini, Davide, Grasso, Antonio Giacomo, Gori, Davide, Belotti, Tamara, Prete, Arcangelo, Masetti, Riccardo |
| سنة النشر: | 2024 |
| المجموعة: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| مصطلحات موضوعية: | Hematology, Bone Marrow |
| الوصف: | Steroid-refractory graft-versus-host disease (SR-GvHD) represents a major complication of pediatric allogenic hematopoietic stem cell transplantation. Ruxolitinib, a selective JAK 1-2 inhibitor, showed promising results in the treatment of SR-GvHD in adult trial, including patients >12 years old. This systematic review aims to evaluate ruxolitinib use for SR-GvHD in the pediatric population. Among the 12 studies included, ruxolitinib administration presented slight differences. Overall response rate (ORR) ranged from 45% to 100% in both acute and chronic GvHD. Complete response rates (CR) varied from 9% to 67% and from 0% to 28% in aGvHD and cGvHD, respectively. Individual-patient meta-analysis from 108 children under 12 years showed an ORR and CR for aGvHD of 74% and 56%, respectively, while in cGvHD ORR was 78% but with only 11% achieving CR. Treatment-related toxicities were observed in 20% of patients, including cytopenia, liver toxicity, and infections. Age, weight, graft source, previous lines of therapy, and dose did not significantly predict response, while a higher rate of toxicities was observed in aGvHD patients. In conclusion, ruxolitinib shows promising results in the treatment of SR-GvHD in children, including those under 12 years. Specific pediatric perspective trials are currently ongoing to definitely assess its efficacy and safety. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/38402346; info:eu-repo/semantics/altIdentifier/wos/WOS:001173223400001; volume:N/A; firstpage:1; lastpage:12; numberofpages:12; journal:BONE MARROW TRANSPLANTATION; https://hdl.handle.net/11585/962503Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85187283196; https://www.nature.com/articles/s41409-024-02252-zTest |
| DOI: | 10.1038/s41409-024-02252-z |
| الإتاحة: | https://doi.org/10.1038/s41409-024-02252-zTest https://hdl.handle.net/11585/962503Test https://www.nature.com/articles/s41409-024-02252-zTest |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.2083531E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41409-024-02252-z |
|---|